4:47 PM
 | 
Feb 22, 2019
 |  BioCentury  |  Tools & Techniques

Modeling now for precision later

How GNS wants to make pay-for-performance unnecessary

GNS Healthcare Inc. is building a platform that aims to make value-based payment models unnecessary by giving companies a way to know which patients will respond before they even launch the drug.

While drug companies and payers are entering conversations about how to structure reimbursement to ensure payers are compensated for treatments that don’t perform as promised, GNS is looking beyond, using machine learning to build models that can dial in the most responsive patient population from the start.

Part of the picture is the idea of virtual patients, designed via the integration of real world evidence and clinical data through GNS’s causal learning platform.

GNS’s reverse engineering and forward simulation (REFS) platform is a hypothesis-free, causal machine learning technology that uses Bayesian network inference to build disease models. As it brings in more data, it learns from the information and updates its parameters and models accordingly.

The platform leverages genomic, clinical and real world data from electronic medical records, wearable devices and patient registries to characterize which patients are most likely to respond to a given therapy.

“These things have come together to enable increasingly accurate models of human diseases, which allows us to simulate the variety of available treatments to determine what works better for whom and move past a world where patients are treated like guinea pigs,” said Chairman, CEO and co-founder Colin Hill.

In the last eight years, the company has built a suite of partnerships with drug companies and payers, and in many cases works across a spectrum of stakeholders, to deliver a tailored signature for the set of patients most likely to respond to a given therapy within a year or two of launch.

“In some way, I’d say that value-based pricing arrangements are just a crutch where you don’t have the precision yet.”

Colin Hill, GNS Healthcare

While GNS isn’t disclosing its drug company clients, Hill said at least one drug has launched that used the REFS platform...

Read the full 1619 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >